Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

To join this study, you would need to be an adult (18 or older) with B-cell lymphoma that has come back or not responded to previous treatments. Doctors would need to see that your lymphoma can be measured, and your important organs (like your heart, kidneys, and liver) are working well. Your body's ability to make blood cells (bone marrow function) also needs to be healthy enough.

You would not be able to join if you've already had certain types of gene-based cell therapies. You also can't have serious uncontrolled infections or certain long-term conditions like uncontrolled heart problems, specific types of autoimmune diseases needing strong medicines, or a history of certain other cancers or stem cell transplants recently. Careful checks will be done for conditions such as HIV, Hepatitis B, or Hepatitis C, or any active problems in your brain or spinal cord.

If you decide to take part in this study, you will first have some standard chemotherapy using medicines called Cyclophosphamide and Fludarabine. After this, you would receive either KITE-363 or KITE-753, which are the main drugs being tested. The study involves regular visits to the clinic for check-ups, blood tests, and scans to see how your body is responding to the treatment and to monitor for any side effects. You will be closely looked after during this time.

Once you have received the study drug, your health will continue to be monitored for a very long time, for up to 15 years. This long-term follow-up is important to understand how the new treatments affect people over many years. The study team will explain exactly what this involves, but it usually includes periodic check-ups and tests. The total duration of active treatment and close monitoring may vary, but the overall follow-up is for a significant period.